Effect of peri-operative magnesium sulfate infusion on inflammatory factors in patients with lung cancer

Not Applicable

Conditions: ung cancer.
Malignant neoplasm of bronchus and lung

Registration Number: IRCT20120305009213N5

Lead Sponsor: Cancer institute

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 44

Inclusion Criteria

Patients with stage I (cT1N0 and cT2N0), stage II (cT1N1, cT2N1 and cT3N0) lung cancer
Age 18 to 65 years old
Candidate for lobectomy or pneumoectomy surgery
Informed consent

Exclusion Criteria

History of severe heart disease, severe systemic and functional lung disease (asthma, COPD)
Electrolyte disturbance
BMI below 16
concurrent history of other cancers
Albumin level less than 5.2
stage IIIA (cT3N1 and cT1–3N2) lung cancer and above
Small cell carcinoma
HIV positive or any immunodeficiency
Patients undergoing clinical trial studies at the same time as this study
Dissatisfaction with participating in the study
Incomplete tumor resection (potential effect on cytokine levels)
Long incision on chest wall, diaphragm or mediastinum
Prescribing corticosteroids
Pulmonary fibrosis (affected IL-8)
History of chemotherapy and radiotherapy during the past month
Patients with severe chronic renal failure (creatinine clearance less than 30 ml / min)
Patients with acute renal failure and anuria
Patients treated with drugs that produce hypermagnesemia (such as spironolactone, eplerenone)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of blood levels of inflammatory (IL6, IL8) and anti-inflammatory (IL10, TGF-B) factors in the study groups. Timepoint: A blood sample is collected as a control immediately after induction of anesthesia and then another sample one day after surgery. Method of measurement: Using ELISA test.

Secondary Outcome Measures